Prelude Therapeutics Inc
- Last sale
- Nov 12, 2026 · -7.12%
- Market cap
- $280.91M
- 79.8M shares
- Filings
- 391
Q2 2026+73.4% FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026derivedN/M FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026+182.6% FY25 yoy
- $280.91M
- —
- 12.5×
- 2.1×
- -11.84%
- —
Twelve months to Jun 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $12,140,000 | reported | |
| FY 2024 | 2024-12-31 | $7,000,000 | reported |
Pharmaceutical preparations
Prelude Therapeutics Inc is the 166th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
PYXSPyxis Oncology, Inc.$13.9M14.2%574.5%$189.0MCVSICV Sciences, Inc.$13.8M12.2%6.9%$2.3MPTNPalatin Technologies Inc$13.2M—63.5%$12.2MTNXPTonix Pharmaceuticals Holding Corp.$13.1M29.8%946.2%$62.6MEVMNEvommune, Inc.$13.0M85.7%529.8%$241.9MEMMAEmmaus Life Sciences, Inc.$12.5M25.2%60.2%$4.2M
PRLDPrelude Therapeutics Inc (this company)$12.1M73.4%819.6%$280.9M
JAGXJaguar Health, Inc.$11.5M1.5%465.4%$2.0MCBIOCrescent Biopharma, Inc.$10.8M—1,419.6%$561.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Prelude Therapeutics Inc · CIK 1678660 · Engraved from SEC EDGAR